Scholar Rock SMA drug approved by FDA
Published . Updated .
Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard therapies.
Directly affected
- PPLI People
Named in this report.
- SRRK SCHOLAR ROCK HOLDING CORP
The reported development directly names SCHOLAR ROCK HOLDING CORP in the headline; GA resolved that company to SRRK.
Indirectly affected
- BNR BURNING ROCK BIOTECH LTD
GA selected BNR as a RELATED security because its canonical security name directly matches this event's themes: biotech, rock. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard therapies.
Source: BioPharma Dive
How far Scholar Rock Holding (SRRK) has moved since 14 Sep 2026
Since the first closing price after “Scholar Rock SMA drug approved by FDA,” Scholar Rock Holding (SRRK) is -19.46%. The S&P 500 fund (SPY) is +1.21% over the same days, a -20.67% difference versus the market.
Disclosure records for Scholar Rock Holding (SRRK) within two months of 14 Sep 2026
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Scholar Rock Holding (SRRK)
Companies tied to this story
- SRRK Scholar Rock Holding
In “Scholar Rock SMA drug approved by FDA,” Scholar Rock Holding (SRRK) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names SCHOLAR ROCK HOLDING CORP in the headline; GA resolved that company to SRRK
- BNR Burning Rock Biotech
In “Scholar Rock SMA drug approved by FDA,” Burning Rock Biotech (BNR) is linked, with no stored direction, medium confidence. Reason on file: GA selected BNR as a RELATED security because its canonical security name directly matches this event's themes: biotech, rock. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACHC Acadia Healthcare
In “Scholar Rock SMA drug approved by FDA,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “Scholar Rock SMA drug approved by FDA,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “Scholar Rock SMA drug approved by FDA.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “Scholar Rock SMA drug approved by FDA.” Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
For “Scholar Rock SMA drug approved by FDA,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
How “Scholar Rock SMA drug approved by FDA” reaches Scholar Rock Holding (SRRK)
On 14 Sep 2026, “Scholar Rock SMA drug approved by FDA” is the story that connects Scholar Rock Holding (SRRK) to this story.
Scholar Rock Holding (SRRK) is on the page because The reported development directly names SCHOLAR ROCK HOLDING CORP in the headline; GA resolved that company to SRRK
Also listed, Burning Rock Biotech (BNR): GA selected BNR as a RELATED security because its canonical security name directly matches this event's themes: biotech, rock. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Scholar Rock Holding (SRRK) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. BNR traded between 11.56 and 19.11 across 20 sessions. The latest close on file is 12.45. SRRK traded between 38.88 and 51.67 across 20 sessions. The latest close on file is 40.27.
How strong the case is around Scholar Rock Holding (SRRK)
46 out of 100
“Scholar Rock SMA drug approved by FDA” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.